TMEM8B

Across TCGA pan-cancer cohorts, TMEM8B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM8B data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM8B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM8B expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where TMEM8B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.937	0.258	.013	17	view →
LSCC	OS	Median	All	1.000	0.924	.007	11	view →
HNSC	OS	Median	III,IV	0.635	0.879	.030	3	view →
PDAC	DFS	Tertile	III,IV	0.938	0.344	.036	3	view →
CCRCC	DFS	Median	IV	0.099	0.758	.024	3	view →
GBM	OS	Quartile	All	0.921	0.694	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM8B–LUAD (DFS)

Open the LUAD breakdown →